Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay

Overview

Journal Front Neurol

Specialty Neurology

Date 2021 Dec 13

PMID 34899578

Citations 5

Authors

Jiting Zhu

Yuanyuan Zhang

Runyun Li

Yi Lin

Ying Fu

Yaping Yan

Wenli Zhu

Ning Wang

Zaiqiang Zhang

Guorong Xu

Affiliations

Soon will be listed here.

Abstract

This study aimed to determine the diagnostic efficiency of a novel immunoblotting detection assay for anti-ganglioside antibodies (AGAs) in the Guillain-Barre syndrome (GBS). Serum immunoglobulin (IgG and IgM) of AGAs were measured in 121 participants from a registered cohort study of immune-mediated neuropathies and 29 healthy controls by immunoblotting panel assay. Sensitivity, specificity, and positive predictive value (PPV) of the assay were compared to calculate the diagnostic accuracy. In our cohort, any of the AGAs were positive in 42.4% of the GBS patients. The sensitivity and specificity of AGAs (both IgG and IgM) in the diagnosis of GSB were 42 and 76% while for IgG-AGAs were 35 and 87%. AGAs positivity had a significant association with the AMAN subtype ( = 0.0004), and the sensitivity, specificity of AGAs in AMAN were 86, 69%, respectively with high (AUC = 0.78, = 0.002) discriminative powers. GM1-IgG AGA was more common and specific to AMAN patients than other GBS forms ( = 0.008). Our novel immunoblotting detection assay could complement GBS diagnosis. IgG-AGAs were more likely to be detected in GBS, and GM1-IgG AGA could assist AMAN diagnosis.

Citing Articles

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19.

Orak S, Cerci Kubur C, Atasever A, Polat M Arch Pediatr. 2023; 30(4):236-239.

PMID: 37069023 PMC: 10027943. DOI: 10.1016/j.arcped.2023.02.010.

Diagnostic Pitfalls in Guillain-Barré Syndrome: Case Report and Literature Review.

Lupu V, Miron I, Cianga A, Gavrilovici C, Grigore I, David A Children (Basel). 2022; 9(12).

PMID: 36553412 PMC: 9776903. DOI: 10.3390/children9121969.

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy.

Kim S, Lee E, Sohn E Sci Rep. 2022; 12(1):18562.

PMID: 36329046 PMC: 9633831. DOI: 10.1038/s41598-022-19547-0.

Weakness in both lower limbs for 1 week and blepharoptosis for 3 days in a boy aged 1 year and 7 months.

Lang C, Tian M, Shu X Zhongguo Dang Dai Er Ke Za Zhi. 2022; 24(8):923-927.

PMID: 36036132 PMC: 9425863. DOI: 10.7499/j.issn.1008-8830.2203101.

Impact of Antecedent Infections on the Antibodies against Gangliosides and Ganglioside Complexes in Guillain-Barré Syndrome: A Correlative Study.

Dutta D, Debnath M, Seshagiri D, Nair B, Das S, Wahatule R Ann Indian Acad Neurol. 2022; 25(3):401-406.

PMID: 35936588 PMC: 9350806. DOI: 10.4103/aian.aian_121_22.

References

Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R . Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2010; 29(3):599-612. DOI: 10.1016/j.vaccine.2010.06.003. View

. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first.... J Peripher Nerv Syst. 2011; 15(4):295-301. DOI: 10.1111/j.1529-8027.2010.00290.x. View

Fan C, Jin H, Hao H, Gao F, Sun Y, Lu Y . Anti-ganglioside antibodies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. Muscle Nerve. 2016; 55(4):470-475. DOI: 10.1002/mus.25266. View

Franciotta D, Gastaldi M, Biagioli T, Benedetti L, Giannotta C, Bedin R . Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme. Clin Chem Lab Med. 2018; 56(11):1921-1925. DOI: 10.1515/cclm-2018-0234. View

Gastaldi M, Zardini E, Scaranzin S, Uccelli A, Andreetta F, Baggi F . Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Front Neurol. 2020; 10:1385. PMC: 6971200. DOI: 10.3389/fneur.2019.01385. View

Rinaldi S, Brennan K, Kalna G, Walgaard C, van Doorn P, Jacobs B . Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS One. 2013; 8(12):e82337. PMC: 3864991. DOI: 10.1371/journal.pone.0082337. View

Kusunoki S, Willison H, Jacobs B . Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. J Neurol Neurosurg Psychiatry. 2020; 92(3):311-318. DOI: 10.1136/jnnp-2020-325053. View

. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978; 3(6):565-6. DOI: 10.1002/ana.410030628. View

Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S . Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry. 2011; 83(1):23-8. DOI: 10.1136/jnnp-2011-300309. View

10.

Kieseier B, Mathey E, Sommer C, Hartung H . Immune-mediated neuropathies. Nat Rev Dis Primers. 2018; 4(1):31. DOI: 10.1038/s41572-018-0027-2. View

11.

Wahatule R, Dutta D, Debnath M, Nagappa M, Mahadevan A, Sinha S . Ganglioside complex antibodies in an Indian cohort of Guillain-Barré syndrome. Muscle Nerve. 2020; 62(6):728-734. DOI: 10.1002/mus.27071. View

12.

Ho T, Willison H, Nachamkin I, Li C, Veitch J, Ung H . Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 1999; 45(2):168-73. DOI: 10.1002/1531-8249(199902)45:2<168::aid-ana6>3.0.co;2-6. View

13.

Shahrizaila N, Kokubun N, Sawai S, Umapathi T, Chan Y, Kuwabara S . Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology. 2014; 83(2):118-24. PMC: 4117169. DOI: 10.1212/WNL.0000000000000577. View

14.

. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve.... J Peripher Nerv Syst. 2010; 15(3):185-95. DOI: 10.1111/j.1529-8027.2010.00278.x. View

15.

Irie S, Saito T, Kanazawa N, Ogino M, Ogino Y, Sakai F . Detection of serum anti-ganglioside antibodies by latex agglutination assay in Guillain-Barré syndrome: comparison with ELISA. Intern Med. 2003; 42(6):490-5. DOI: 10.2169/internalmedicine.42.490. View

16.

Bonyadi M, Barzegar M, Badalzadeh R, Hashemilar M . Comparison of immunoblotting and ELISA for detection of anti-ganglioside antibodies in children with Guillain-Barre syndrome. Iran J Immunol. 2010; 7(2):117-23. DOI: IJIv7i2A7. View

17.

Galban-Horcajo F, Halstead S, McGonigal R, Willison H . The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Curr Opin Chem Biol. 2014; 18:78-86. DOI: 10.1016/j.cbpa.2014.01.008. View

18.

Leonhard S, Mandarakas M, Gondim F, Bateman K, Ferreira M, Cornblath D . Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019; 15(11):671-683. PMC: 6821638. DOI: 10.1038/s41582-019-0250-9. View

19.

Rinaldi S, Brennan K, Willison H . Combinatorial glycoarray. Methods Mol Biol. 2011; 808:413-23. DOI: 10.1007/978-1-61779-373-8_28. View

20.

Sejvar J, Baughman A, Wise M, Morgan O . Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2):123-33. PMC: 5703046. DOI: 10.1159/000324710. View